Posted by Michael Wonder on 21 Aug 2025
Japan’s PMDA had shortest review times for new drugs, half of drugs submitted to US first
20 August 2025 - According to a recent analysis, Japanese regulators have the shortest time to approval for new drugs compared to their European, Australian, and US counterparts.
The analysis also found that a majority of sponsors submit applications to the US FDA before regulators in other markets.
